阿莫西林/克拉维酸钾对慢性阻塞性肺疾病急性加重期住院治疗患者的疗效及安全性评价  

The evaluation on the therapeutic efficacy and safety of amoxicillin-potassium clavulanate in treating in-patients with acute exacerbation of chronic obstructed pulmonary disease

作　　者：杨秀云[1] 徐祖建[1] 林文霞[1] 叶宏波[1] 章丽娟[1] 卢艳萍[1] 杨江明[1] 张天翼[1] 

机构地区：[1]浙江省台州医院路桥院区,浙江台州318050

出　　处：《现代中西医结合杂志》2007年第33期4917-4918,4923,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察阿莫西林/克拉维酸钾对慢性阻塞性肺疾病急性加重住院治疗患者经验性抗感染治疗的疗效及安全性。方法纳入慢性阻塞性肺疾病急性加重住院治疗患者82例,排除严重的伴随疾病。随机分为2组,治疗组40例应用阿莫西林/克拉维酸钾针治疗,对照组42例应用阿洛西林钠治疗,分别对其临床疗效、细菌学疗效和不良反应进行评价。结果治疗组和对照组治疗临床有效率分别为93%和74%,2组比较有显著性差异(P<0.05);细菌总清除率分别为89%和66%,2组比较有显著性差异(P<0.05);不良反应发生率分别为8%和7%,2组比较无显著性差异(P>0.05)。结论阿莫西林/克拉维酸钾是慢性阻塞性肺疾病急性加重住院治疗患者经验性抗感染治疗肯定而且安全的抗菌药物。Objective It is to observe the therapeutic efficacy and safety of amoxicillin-potassium clavulanate in treating inpatients with acute exacerbation of chronic obstructed pulmonary disease （AECOPD）. Methods 82 in-patients with AECOPD without other diseases were included and divided into two groups randomly. 40 cases of them from pilot group were treated with amoxicillin-potassium clavulanate and the rest 42 cases from control group with azlocillin sodium injection. The clinical, bacterial therapeutic efficacy and side-effects of the both groups were observed and compared. Results The clinical effective rates of the pilot group and control group were 93 % and 74 % respectively with significant difference statistically （P 〈 0.05）, and the total bacterial clearance rates of them were 89 % and 66 % respectively, also with significant difference statistically （P 〈 0.05）, while the rates of side-effects of them were not significantly different in statistics （7.5 % and 7.1% respectively）. Conclusion Amoxicillin-potassium clavulanate is an effective and safe antibiotic in treating in-patients with AE- COPD.

关 键 词：阿莫西林/克拉维酸钾 慢性阻塞性肺疾病急性加重期 细菌感染 有效性 安全性 

分 类 号：R563[医药卫生—呼吸系统]